For women with diabetes, vaginal yeast infections are more likely to be caused by a non-albicans species.2,9,10

  • For non-albicans VVC, CDC Guidelines suggest a longer duration of therapy (7-14 days) with a non-fluconazole azole regimen as first-line therapy2
  • Miconazole, the active ingredient in MONISTAT®, treats C. glabrata—the most prevalent non-albicans species—while prescription azoles do not.16

MONISTAT® 7 meets the CDC Guidelines for treating non-albicans VVC.

For women on certain antidiabetic drugs, fluconazole may increase the risk of serious hypoglycemic episodes.11,12

  • Fluconazole can interact with sulfonylureas (commonly used oral hypoglycemic drugs), which can increase drug plasma levels and lead to clinically dangerous episodes of hypoglycemia11-13

In a recent survey, 73% of OB/GYNs said they recommend fluconazole for vaginal yeast infection in women with diabetes more than butoconazole, miconazole, or terconazole.15 The prevalence of non-albicans species and potential drug interactions may warrant closer attention to VVC in patients with diabetes.

For vaginal yeast infection in patients with diabetes, recommend MONISTAT® 7.